JAPANESE TRADE AGREEMENT COULD BOOST U.S. MEDICAL SALES TO JAPAN BY $500 MIL.
This article was originally published in The Gray Sheet
JAPANESE TRADE AGREEMENT COULD BOOST U.S. MEDICAL SALES TO JAPAN BY $500 MIL. per year three years after the agreement takes effect on Nov. 1, the Health Industry Manufacturers Association estimates. HIMA, which served as an advisor to the U.S. trade team during the negotiations, predicts that under the trade accord, U.S. sales to government-managed hospitals, research facilities and critical care centers in Japan will increase from current levels of $700 mil. per year, to nearly $1 bil. after three years, while annual sales to Japan's private medical sector are expected to increase $200 mil.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.